Intertek Group has acquired Quantitative Technologies Inc. (QTI), a contract analytical research and development laboratory. QTI has served the North American market for more than 15 years, specializing in the pre-market launch stages of the drug and product development life cycle. QTI is located in Whitehouse, NJ with approximately 60 employees and a cGMP lab.

The acquisition is intended to advance Intertek’s strategic growth in expert support services to the global pharmaceutical, medical device and drug delivery industry. QTI will operate in the Intertek OCA Division (Caleb Brett) Pharmaceutical Services group. That group’s chief executive officer, Mark Loughead, commented, “QTI has an outstanding reputation in the industry and will further expand our ability to support the pharmaceutical and related sectors for outsourced R&D and testing expertise.”

John Conti-Ramsden, Ph.D., global director for Intertek Pharmaceutical Services, added, “The acquisition of QTI further develops Intertek’s USA offering and global platform in the area of pharmaceutical services. Intertek already provides a wide range of testing services to pharmaceutical clients from its laboratories in Europe and GLP bioanalytical services from the Alta laboratories in California.”